Trials / Completed
CompletedNCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC. |
| DRUG | Ethinyl Estradiol | Administered orally |
| DRUG | Drospirenone | Administered orally |
Timeline
- Start date
- 2023-09-12
- Primary completion
- 2024-07-11
- Completion
- 2024-07-11
- First posted
- 2023-09-15
- Last updated
- 2024-07-26
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06039826. Inclusion in this directory is not an endorsement.